Detalles de la búsqueda
1.
Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.
Infect Dis Ther
; 13(2): 401-411, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38291279
2.
Clinical characteristics and treatment patterns of patients with episodic cluster headache: results from the United States, United Kingdom and Germany.
Curr Med Res Opin
; 39(12): 1637-1647, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37615206
3.
Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN).
J Med Econ
; 25(1): 1030-1038, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35971655
4.
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).
Clin Drug Investig
; 42(3): 263-275, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35041159
5.
Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials.
J Med Econ
; 25(1): 630-639, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35510376
6.
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial.
Open Forum Infect Dis
; 9(5): ofac172, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35493124
7.
Patient-Reported Outcomes for Migraine in the US and Europe: Burden Associated with Multiple Preventive Treatment Failures.
Clinicoecon Outcomes Res
; 13: 647-660, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34285524
8.
Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm.
Adv Ther
; 38(8): 4442-4460, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264500
9.
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
Adv Ther
; 38(11): 5465-5483, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34542830
10.
Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study.
J Pain Res
; 13: 3531-3538, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33408512
11.
A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe.
J Patient Rep Outcomes
; 4(1): 53, 2020 Jul 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32632891
12.
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Lancet Neurol
; 19(10): 814-825, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32949542
13.
Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey.
J Med Econ
; 22(9): 849-858, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30977712
14.
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic.
Lancet Infect Dis
; 22(11): 1531, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36174596
15.
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).
Clin Drug Investig
; 42(3): 277, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35254628
Resultados
1 -
15
de 15
1
Próxima >
>>